Cargando…
Caregiver perspective on pediatric attention-deficit/hyperactivity disorder: medication satisfaction and symptom control
The caregiver perspective on pediatric attention-deficit/hyperactivity disorder (ADHD) study (CAPPA) was a web-based, cross-sectional survey of caregivers of children and adolescents (6–17 years of age) with ADHD and was conducted in 10 European countries. CAPPA included caregiver assessments of glo...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315351/ https://www.ncbi.nlm.nih.gov/pubmed/28243096 http://dx.doi.org/10.2147/NDT.S121639 |
_version_ | 1782508676660068352 |
---|---|
author | Fridman, Moshe Banaschewski, Tobias Sikirica, Vanja Quintero, Javier Erder, M Haim Chen, Kristina S |
author_facet | Fridman, Moshe Banaschewski, Tobias Sikirica, Vanja Quintero, Javier Erder, M Haim Chen, Kristina S |
author_sort | Fridman, Moshe |
collection | PubMed |
description | The caregiver perspective on pediatric attention-deficit/hyperactivity disorder (ADHD) study (CAPPA) was a web-based, cross-sectional survey of caregivers of children and adolescents (6–17 years of age) with ADHD and was conducted in 10 European countries. CAPPA included caregiver assessments of global medication satisfaction, global symptom control, and satisfaction with ADHD medication attributes. Overall, 2,326 caregiver responses indicated that their child or adolescent was currently receiving ADHD medication and completed the “off medication” assessment required for inclusion in the present analyses. Responses to the single-item global medication satisfaction question indicated that 88% were satisfied (moderately satisfied to very satisfied) with current medication and 18% were “very satisfied” on the single-item question. Responses to the single-item global symptom control question indicated that 47% and 19% of caregivers considered their child or adolescent’s symptoms to be “controlled” or “very well controlled”, respectively. Significant variations in response to the questions of medication satisfaction and symptom control were observed between countries. The correlation between the global medication satisfaction and global symptom control questions was 0.677 (P<0.001). Global medication satisfaction was significantly correlated (P<0.001) with all assessed medication attributes, with the highest correlations observed for symptom control (r=0.601) and effect duration (r=0.449). Correlations of medication attributes with global symptom control were generally lower than with global medication satisfaction but were all statistically significant (P<0.001). CAPPA medication satisfaction and symptom control were also significantly correlated (P<0.001) with symptom control as based on the ADHD-Rating Scale-IV symptom score and the number of bad days per month when on medication. In conclusion, caregiver responses in this European sample suggest that current treatment could potentially be improved. The observed correlations of global medication satisfaction with global symptom control and other CAPPA assessments, including medication attributes, provide support for the inter-connectivity of the medication satisfaction and symptom control. |
format | Online Article Text |
id | pubmed-5315351 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-53153512017-02-27 Caregiver perspective on pediatric attention-deficit/hyperactivity disorder: medication satisfaction and symptom control Fridman, Moshe Banaschewski, Tobias Sikirica, Vanja Quintero, Javier Erder, M Haim Chen, Kristina S Neuropsychiatr Dis Treat Original Research The caregiver perspective on pediatric attention-deficit/hyperactivity disorder (ADHD) study (CAPPA) was a web-based, cross-sectional survey of caregivers of children and adolescents (6–17 years of age) with ADHD and was conducted in 10 European countries. CAPPA included caregiver assessments of global medication satisfaction, global symptom control, and satisfaction with ADHD medication attributes. Overall, 2,326 caregiver responses indicated that their child or adolescent was currently receiving ADHD medication and completed the “off medication” assessment required for inclusion in the present analyses. Responses to the single-item global medication satisfaction question indicated that 88% were satisfied (moderately satisfied to very satisfied) with current medication and 18% were “very satisfied” on the single-item question. Responses to the single-item global symptom control question indicated that 47% and 19% of caregivers considered their child or adolescent’s symptoms to be “controlled” or “very well controlled”, respectively. Significant variations in response to the questions of medication satisfaction and symptom control were observed between countries. The correlation between the global medication satisfaction and global symptom control questions was 0.677 (P<0.001). Global medication satisfaction was significantly correlated (P<0.001) with all assessed medication attributes, with the highest correlations observed for symptom control (r=0.601) and effect duration (r=0.449). Correlations of medication attributes with global symptom control were generally lower than with global medication satisfaction but were all statistically significant (P<0.001). CAPPA medication satisfaction and symptom control were also significantly correlated (P<0.001) with symptom control as based on the ADHD-Rating Scale-IV symptom score and the number of bad days per month when on medication. In conclusion, caregiver responses in this European sample suggest that current treatment could potentially be improved. The observed correlations of global medication satisfaction with global symptom control and other CAPPA assessments, including medication attributes, provide support for the inter-connectivity of the medication satisfaction and symptom control. Dove Medical Press 2017-02-13 /pmc/articles/PMC5315351/ /pubmed/28243096 http://dx.doi.org/10.2147/NDT.S121639 Text en © 2017 Fridman et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Fridman, Moshe Banaschewski, Tobias Sikirica, Vanja Quintero, Javier Erder, M Haim Chen, Kristina S Caregiver perspective on pediatric attention-deficit/hyperactivity disorder: medication satisfaction and symptom control |
title | Caregiver perspective on pediatric attention-deficit/hyperactivity disorder: medication satisfaction and symptom control |
title_full | Caregiver perspective on pediatric attention-deficit/hyperactivity disorder: medication satisfaction and symptom control |
title_fullStr | Caregiver perspective on pediatric attention-deficit/hyperactivity disorder: medication satisfaction and symptom control |
title_full_unstemmed | Caregiver perspective on pediatric attention-deficit/hyperactivity disorder: medication satisfaction and symptom control |
title_short | Caregiver perspective on pediatric attention-deficit/hyperactivity disorder: medication satisfaction and symptom control |
title_sort | caregiver perspective on pediatric attention-deficit/hyperactivity disorder: medication satisfaction and symptom control |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315351/ https://www.ncbi.nlm.nih.gov/pubmed/28243096 http://dx.doi.org/10.2147/NDT.S121639 |
work_keys_str_mv | AT fridmanmoshe caregiverperspectiveonpediatricattentiondeficithyperactivitydisordermedicationsatisfactionandsymptomcontrol AT banaschewskitobias caregiverperspectiveonpediatricattentiondeficithyperactivitydisordermedicationsatisfactionandsymptomcontrol AT sikiricavanja caregiverperspectiveonpediatricattentiondeficithyperactivitydisordermedicationsatisfactionandsymptomcontrol AT quinterojavier caregiverperspectiveonpediatricattentiondeficithyperactivitydisordermedicationsatisfactionandsymptomcontrol AT erdermhaim caregiverperspectiveonpediatricattentiondeficithyperactivitydisordermedicationsatisfactionandsymptomcontrol AT chenkristinas caregiverperspectiveonpediatricattentiondeficithyperactivitydisordermedicationsatisfactionandsymptomcontrol |